PARP1 and atherosclerosis: Recent studies in apoE-/- mice have demonstrated a reduction in atherosclerosis development using an immunodeficiency strategy [20], low dose of the phytochemical tetrahydrocannabinol [76], antioxidant N-Acetylcysteine [77], PARP inhibition [73] or mononuclear cell therapy [63].